Indian Pharma Market Hits 8.1% Growth in August 2025, GLP-1 Sales Surge 97% Driving Anti-Diabetic Boom
1. Indian Pharmaceutical Market Overview (August 2025)
-
Growth: 8.1% YoY growth in August 2025
-
July growth: 7.1%
-
FY25 overall growth: ~8%
-
-
Unit sales: Slight decline of 0.8% in August 2025
-
Key drivers: Chronic therapies, respiratory & oncology drugs
2. Segment-Wise Growth Performance
2.1 Chronic Therapies
-
Overall growth: 12%
-
Breakdown:
-
Cardiac drugs: 11%
-
Anti-diabetic drugs: 11% (boosted by GLP-1 molecules)
-
CNS therapies: 8%
-
2.2 Acute Therapies
-
Overall growth: 6%
-
Breakdown:
-
Anti-infectives: 6%
-
Gastrointestinal drugs: 2%
-
Vitamins, minerals & nutrients: 7%
-
2.3 Other Therapies
-
Respiratory medicines: +19%
-
Oncology: +23%
-
Pain management: +6%
2.4 Highlight: GLP-1 Therapies
-
Month-on-month sales surge: 97%
-
Impact: Major driver for anti-diabetic segment growth
3. Future Market Outlook (FY26)
-
Projected growth: 8-9%
-
Key growth drivers:
-
Faster expansion in chronic therapies
-
Recovery in acute segments
-
Introduction of new product launches
-
4. Global Position & Financial Potential
-
Global ranking:
-
3rd by volume
-
14th by value of production
-
-
Global contribution:
-
50% of global vaccine demand
-
40% of US generic medicines
-
-
Market projections:
-
USD 130 billion by 2030
-
USD 450 billion by 2047
-
5. Government Initiatives Driving Investment
-
Production Linked Incentive (PLI) scheme:
-
55 projects to produce high-end drugs (cancer, diabetes) in India
-
-
Strengthening of Pharmaceuticals Industry (SPI) scheme:
-
Focus on R&D, lab modernization
-
Enhances competitiveness of smaller pharma companies globally
-
6. Key Financial Takeaways
-
Chronic therapies = primary revenue engine (12% growth)
-
Oncology & respiratory segments = high-margin growth areas (23% & 19%)
-
GLP-1 anti-diabetic therapies = fastest-growing segment, strategic for revenue expansion
-
Long-term market potential = USD 450B by 2047
Disclaimer:
The Profit India provides this information for educational and informational purposes only. It does not constitute investment advice, and readers should consult a financial advisor before making investment decisions.
